Insider transactions

EDGAR

EMERGENT BIOSOLUTIONS INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
13 transactions, 111,709 shares
Sum of shares × price per share: 986,069.1752

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 74

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-07 Filed 2026-10-07DeGolyer Donald W Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)17,8007.09
126,202

Derived: shares × price per share. Exact value 126202.00.

111,921Direct (D) Yes
F1, F2
  • F1 Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on October 2, 2026.
  • F2 The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $6.88 to $7.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001583098-26-000008 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-05Williams Paul Anthony Officer: SVP, Products Business
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,0006.53
19,590

Derived: shares × price per share. Exact value 19590.00.

156,098Direct (D) Yes
F1, F2
  • F1 All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
  • F2 The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $6.52 to $6.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001961994-26-000029 Read from the filing’s XML Dispute this row
2026-07-01 Filed 2026-07-02Williams Paul Anthony Officer: SVP, Products Business
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,0008.40
25,200

Derived: shares × price per share. Exact value 25200.00.

159,098Direct (D) Yes
F1, F2
  • F1 All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.31 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001961994-26-000024 Read from the filing’s XML Dispute this row
2026-06-08 Filed 2026-06-10LINDAHL RICHARD S Officer: EVP, Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)3,9648
31,712

Derived: shares × price per share. Exact value 31712.

374,083Direct (D) No
F1
  • F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.
Open filing 0001196632-26-000017 Read from the filing’s XML Dispute this row
2026-06-08 Filed 2026-06-10Williams Paul Anthony Officer: SVP, Products Business
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)6948
5,552

Derived: shares × price per share. Exact value 5552.

162,098Direct (D) No
F1
  • F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.
Open filing 0001961994-26-000021 Read from the filing’s XML Dispute this row
2026-06-08 Filed 2026-06-10Hartzel William Officer: SVP, Bioservices
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,7418
13,928

Derived: shares × price per share. Exact value 13928.

185,558Direct (D) No
F1
  • F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
Open filing 0001989644-26-000011 Read from the filing’s XML Dispute this row
2026-06-08 Filed 2026-06-10Glessner Coleen Officer: EVP, Quality Ethics, and CPL
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,0188
16,144

Derived: shares × price per share. Exact value 16144.

202,201Direct (D) No
F1
  • F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.
Open filing 0001919170-26-000016 Read from the filing’s XML Dispute this row
2026-05-01 Filed 2026-05-04Dayal Sujata Tyagi Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)12,7818.36
106,849.16

Derived: shares × price per share. Exact value 106849.16.

101,543Direct (D) Yes
F2, F3
  • F2 Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 8, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
  • F3 The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.70 to $8.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001536908-26-000004 Read from the filing’s XML Dispute this row
2026-05-01 Filed 2026-05-04Dayal Sujata Tyagi Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9808.94
8,761.2

Derived: shares × price per share. Exact value 8761.20.

100,563Direct (D) Yes
F2, F4
  • F2 Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 8, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
  • F4 The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.70 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001536908-26-000004 Read from the filing’s XML Dispute this row
2026-05-01 Filed 2026-05-04DeGolyer Donald W Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)14,5278.36
121,445.72

Derived: shares × price per share. Exact value 121445.72.

130,675Direct (D) Yes
F2, F3
  • F2 Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
  • F3 The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.78 to $8.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001583098-26-000004 Read from the filing’s XML Dispute this row
2026-05-01 Filed 2026-05-04DeGolyer Donald W Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9548.96
8,547.84

Derived: shares × price per share. Exact value 8547.84.

129,721Direct (D) Yes
F2, F4
  • F2 Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
  • F4 The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.80 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001583098-26-000004 Read from the filing’s XML Dispute this row
2026-05-01 Filed 2026-05-04Zoon Kathryn C Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)16,1458.36
134,972.2

Derived: shares × price per share. Exact value 134972.20.

80,998Direct (D) Yes
F2, F3
  • F2 Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
  • F3 The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.77 to $8.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001685720-26-000003 Read from the filing’s XML Dispute this row
2026-05-01 Filed 2026-05-04Zoon Kathryn C Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,0578.97
9,481.29

Derived: shares × price per share. Exact value 9481.29.

79,941Direct (D) Yes
F2, F4
  • F2 Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
  • F4 The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.79 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001685720-26-000003 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Fowler Neal Franklin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,3440—160,847Direct (D) No
F1
  • F1 Represents an annual grant of restricted stock units (RSUs) granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the Company) common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (Annual Grant Vesting Date), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
Open filing 0001493692-26-000003 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Fowler Neal Franklin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,296) — exercise price 7.99
Acquired (A)11,2960—11,296Direct (D) No
F2, F3
  • F2 Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
  • F3 The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001493692-26-000003 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Dayal Sujata Tyagi Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,3440—114,324Direct (D) Yes
F1
  • F1 Represents an annual grant of restricted stock units (RSUs) granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the Company) common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (Annual Grant Vesting Date), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
Open filing 0001536908-26-000004 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Dayal Sujata Tyagi Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,296) — exercise price 7.99
Acquired (A)11,2960—11,296Direct (D) Yes
F5, F6
  • F5 Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
  • F6 The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001536908-26-000004 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Harsanyi Zsolt Director · Officer: Chairman
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,3440—149,076Direct (D) No
F1
  • F1 Represents an annual grant of restricted stock units (RSUs) granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the Company) common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (Annual Grant Vesting Date), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
Open filing 0001380184-26-000005 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Harsanyi Zsolt Director · Officer: Chairman
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,296) — exercise price 7.99
Acquired (A)11,2960—11,296Direct (D) No
F2, F3
  • F2 Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
  • F3 The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001380184-26-000005 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04DeGolyer Donald W Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,3440—145,202Direct (D) Yes
F1
  • F1 Represents an annual grant of restricted stock units (RSUs) granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the Company) common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (Annual Grant Vesting Date), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
Open filing 0001583098-26-000004 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04DeGolyer Donald W Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,296) — exercise price 7.99
Acquired (A)11,2960—11,296Direct (D) Yes
F5, F6
  • F5 Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
  • F6 The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001583098-26-000004 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Zoon Kathryn C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,3440—97,143Direct (D) Yes
F1
  • F1 Represents an annual grant of restricted stock units (RSUs) granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the Company) common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (Annual Grant Vesting Date), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
Open filing 0001685720-26-000003 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Zoon Kathryn C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,296) — exercise price 7.99
Acquired (A)11,2960—11,296Direct (D) Yes
F5, F6
  • F5 Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
  • F6 The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001685720-26-000003 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Katkin Keith Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,3440—111,775Direct (D) Yes
F1
  • F1 Represents an annual grant of restricted stock units (RSUs) granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the Company) common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (Annual Grant Vesting Date), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
Open filing 0001314596-26-000002 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Katkin Keith Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)15,4818.28
128,182.68

Derived: shares × price per share. Exact value 128182.68.

96,294Direct (D) Yes
F2, F3
  • F2 Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
  • F3 The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001314596-26-000002 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Katkin Keith Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (11,296) — exercise price 7.99
Acquired (A)11,2960—11,296Direct (D) Yes
F4, F5
  • F4 Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
  • F5 The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001314596-26-000002 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04White Marvin L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,3440—113,839Direct (D) No
F1
  • F1 Represents an annual grant of restricted stock units (RSUs) granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the Company) common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (Annual Grant Vesting Date), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
Open filing 0001493324-26-000002 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04White Marvin L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,296) — exercise price 7.99
Acquired (A)11,2960—11,296Direct (D) No
F2, F3
  • F2 Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
  • F3 The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001493324-26-000002 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04FOWLER JOHN D JR Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,3440—30,350Direct (D) No
F1
  • F1 Represents an annual grant of restricted stock units (RSUs) granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the Company) common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (Annual Grant Vesting Date), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
Open filing 0001190344-26-000012 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04FOWLER JOHN D JR Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,296) — exercise price 7.99
Acquired (A)11,2960—11,296Direct (D) No
F2, F3
  • F2 Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
  • F3 The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001190344-26-000012 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Richard Ronald Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,3440—123,761Direct (D) No
F1
  • F1 Represents an annual grant of restricted stock units (RSUs) granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the Company) common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date (Annual Grant Vesting Date), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
Open filing 0001380177-26-000004 Read from the filing’s XML Dispute this row
2026-04-30 Filed 2026-05-04Richard Ronald Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (11,296) — exercise price 7.99
Acquired (A)11,2960—11,296Direct (D) No
F2, F3
  • F2 Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
  • F3 The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001380177-26-000004 Read from the filing’s XML Dispute this row
2026-04-29 Filed 2026-05-01Hartzel William Officer: SVP, Bioservices
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)100,1110—187,299Direct (D) No
F1, F2
  • F1 The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the Company), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the Amended Stock Incentive Plan), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
  • F2 Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Open filing 0001989644-26-000007 Read from the filing’s XML Dispute this row
2026-04-29 Filed 2026-05-01Williams Paul Anthony Officer: SVP, Products Business
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)100,1110—162,792Direct (D) No
F1, F2
  • F1 The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the Company), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the Amended Stock Incentive Plan), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
  • F2 Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Open filing 0001961994-26-000017 Read from the filing’s XML Dispute this row
2026-04-29 Filed 2026-05-01LINDAHL RICHARD S Officer: EVP, Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)162,6800—378,047Direct (D) No
F1, F2
  • F1 The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the Company), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the Amended Stock Incentive Plan), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
  • F2 Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Open filing 0001196632-26-000013 Read from the filing’s XML Dispute this row
2026-04-29 Filed 2026-05-01PAPA JOSEPH C Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)187,7080—493,153Direct (D) No
F1, F2
  • F1 The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the Company), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the Amended Stock Incentive Plan), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
  • F2 Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Open filing 0001242215-26-000012 Read from the filing’s XML Dispute this row
2026-04-29 Filed 2026-05-01Lowry Simon C Officer: SVP, RD, CMO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)100,1110—177,914Direct (D) No
F1, F2
  • F1 The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the Company), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the Amended Stock Incentive Plan), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
  • F2 Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Open filing 0002044279-26-000007 Read from the filing’s XML Dispute this row
2026-04-29 Filed 2026-05-01Glessner Coleen Officer: EVP, Quality Ethics, and CPL
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)100,1110—204,219Direct (D) No
F1, F2
  • F1 The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the Company), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the Amended Stock Incentive Plan), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
  • F2 Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Open filing 0001919170-26-000012 Read from the filing’s XML Dispute this row
2026-04-29 Filed 2026-05-01Perl Jessica Officer: SVP, General Counsel, Corp Sec
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)104,2820—165,286Direct (D) No
F1, F2
  • F1 The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the Company), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the Amended Stock Incentive Plan), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
  • F2 Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Open filing 0002043716-26-000007 Read from the filing’s XML Dispute this row
2026-04-01 Filed 2026-04-03Williams Paul Anthony Officer: SVP, Products Business
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,0008.44
33,760

Derived: shares × price per share. Exact value 33760.00.

62,681Direct (D) Yes
F1, F2
  • F1 All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001961994-26-000013 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-05Lowry Simon C Officer: SVP, RD, CMO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)10,6368.44
89,767.84

Derived: shares × price per share. Exact value 89767.84.

77,803Direct (D) No
F1
  • F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
Open filing 0002044279-26-000003 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-05LINDAHL RICHARD S Officer: EVP, Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)23,6508.44
199,606

Derived: shares × price per share. Exact value 199606.00.

215,367Direct (D) No
F1
  • F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
Open filing 0001196632-26-000009 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-05Perl Jessica Officer: SVP, General Counsel, Corp Sec
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)6,4658.44
54,564.6

Derived: shares × price per share. Exact value 54564.60.

61,004Direct (D) No
F1
  • F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
Open filing 0002043716-26-000005 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-05Glessner Coleen Officer: EVP, Quality Ethics, and CPL
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)8,1998.44
69,199.56

Derived: shares × price per share. Exact value 69199.56.

104,108Direct (D) No
F1
  • F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
Open filing 0001919170-26-000009 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-05Hartzel William Officer: SVP, Bioservices
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)9,4938.44
80,120.92

Derived: shares × price per share. Exact value 80120.92.

87,188Direct (D) No
F1
  • F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
Open filing 0001989644-26-000005 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-05PAPA JOSEPH C Director · Officer: President and CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)37,0558.44
312,744.2

Derived: shares × price per share. Exact value 312744.20.

305,445Direct (D) No
F1
  • F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of performance stock units.
Open filing 0001242215-26-000008 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-05Williams Paul Anthony Officer: SVP, Products Business
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)9,3978.44
79,310.68

Derived: shares × price per share. Exact value 79310.68.

66,681Direct (D) No
F1
  • F1 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
Open filing 0001961994-26-000009 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Lowry Simon C Officer: SVP, RD, CMO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to buy) — underlying Common Stock (44,834) — exercise price 8.99
Acquired (A)44,8340—147,833Direct (D) No
F2
  • F2 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
Open filing 0002044279-26-000003 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05LINDAHL RICHARD S Officer: EVP, Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to buy) — underlying Common Stock (72,856) — exercise price 8.99
Acquired (A)72,8560—557,346Direct (D) No
F2
  • F2 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
Open filing 0001196632-26-000009 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Perl Jessica Officer: SVP, General Counsel, Corp Sec
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to buy) — underlying Common Stock (46,702) — exercise price 8.99
Acquired (A)46,7020—142,647Direct (D) No
F2
  • F2 Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
Open filing 0002043716-26-000005 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 199

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
AMERICAN CENTURY COMPANIES INC Partly reported under another manager6,624,658 SH43,722,742 dollarsHigher by 3,854,210 Prior quarter: 2,770,448Open filing 0000748054-26-000009 Filed 2026-11-20 Dispute this row
BlackRock, Inc. Partly reported under another manager5,169,634 SH34,119,583 dollarsHigher by 453,035 Prior quarter: 4,716,599Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager2,713,189 SH17,907,047 dollarsLower by 216,049 Prior quarter: 2,929,238Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager2,567,106 SH16,944,474 dollarsLower by 509,540 Prior quarter: 3,076,646Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 2,161,142 SH14,263,537 dollarsLower by 37,697 Prior quarter: 2,198,839Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
LSV ASSET MANAGEMENT Partly reported under another manager1,990,314 SH13,136 dollarsHigher by 294,463 Prior quarter: 1,695,851Open filing 0001050470-26-000015 Filed 2026-11-06 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager1,933,817 SH12,756 dollarsHigher by 589,494 Prior quarter: 1,344,323Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
MILLENNIUM MANAGEMENT LLC 1,881,570 SH12,418,362 dollarsHigher by 809,385 Prior quarter: 1,072,185Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
OAK HILL ADVISORS LP 1,514,015 SH9,992,499 dollarsHigher by 400,677 Prior quarter: 1,113,338Open filing 0001172661-26-005197 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager1,271,161 SH8,391,904 dollarsLower by 66,082 Prior quarter: 1,337,243Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 1,174,335 SH7,750,611 dollarsHigher by 144,964 Prior quarter: 1,029,371Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
Prescott Group Capital Management, L.L.C. 1,143,481 SH7,546,975 dollarsHigher by 370,710 Prior quarter: 772,771Open filing 0001754960-26-000962 Filed 2026-10-30 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,110,951 SH7,332,277 dollarsLower by 89,840 Prior quarter: 1,200,791Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager968,282 SH6,390,661 dollarsHigher by 68,174 Prior quarter: 900,108Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
AQR CAPITAL MANAGEMENT LLC Partly reported under another manager917,845 SH6,057,777 dollarsLower by 123,306 Prior quarter: 1,041,151Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager911,530 SH6,016,098 dollarsLower by 123,891 Prior quarter: 1,035,421Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
PRUDENTIAL FINANCIAL INC Partly reported under another manager873,224 SH5,763,278 dollarsHigher by 67,329 Prior quarter: 805,895Open filing 0001137774-26-000233 Filed 2026-11-16 Dispute this row
Trexquant Investment LP Partly reported under another manager824,639 SH5,442,617 dollarsHigher by 376,781 Prior quarter: 447,858Open filing 0001633445-26-000008 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager732,648 SH4,835,473 dollarsHigher by 518,479 Prior quarter: 214,169Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager724,147 SH4,779,370 dollarsHigher by 40,900 Prior quarter: 683,247Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
Allianz Asset Management GmbH Partly reported under another manager673,869 SH4,447,535 dollarsHigher by 130,088 Prior quarter: 543,781Open filing 0001193125-26-463640 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager586,729 SH3,872,412 dollarsLower by 34,744 Prior quarter: 621,473Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager545,694 SH3,601,584 dollarsHigher by 75,979 Prior quarter: 469,715Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 504,117 SH2,974,290 dollarsHigher by 63,694 Prior quarter: 440,423Open filing 0001423442-26-000004 Filed 2026-11-12 Dispute this row
FEDERATED HERMES, INC. Partly reported under another manager470,739 SH3,106,877 dollarsLower by 360,386 Prior quarter: 831,125Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager467,420 SH3,084,985 dollarsLower by 392,062 Prior quarter: 859,482Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
PANAGORA ASSET MANAGEMENT INC 452,516 SH2,986,606 dollarsHigher by 123,456 Prior quarter: 329,060Open filing 0000883677-26-000011 Filed 2026-11-12 Dispute this row
BRIDGEWAY CAPITAL MANAGEMENT, LLC 377,905 SH2,494,173 dollarsNot in the prior quarter’s filings read Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 340,958 SH2,250,323 dollarsLower by 762 Prior quarter: 341,720Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager321,715 SH2,123,319 dollarsLower by 44,296 Prior quarter: 366,011Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Squarepoint Ops LLC Partly reported under another manager317,367 SH2,094,622 dollarsHigher by 169,351 Prior quarter: 148,016Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row
Values First Advisors, Inc. 296,098 SH1,954,247 dollarsLower by 5,390 Prior quarter: 301,488Open filing 0001398344-26-018674 Filed 2026-10-23 Dispute this row
TRUIST FINANCIAL CORP Partly reported under another manager230,092 SH1,518,607 dollarsHigher by 186,421 Prior quarter: 43,671Open filing 0000092230-26-000130 Filed 2026-10-30 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager216,147 SH1,426,568 dollarsLower by 3,514 Prior quarter: 219,661Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
Soviero Asset Management, LP 210,000 SH1,386,000 dollarsHigher by 110,000 Prior quarter: 100,000Open filing 0001013594-26-001184 Filed 2026-11-16 Dispute this row
GLOBEFLEX CAPITAL L P 198,526 SH1,310,272 dollarsLower by 42,772 Prior quarter: 241,298Open filing 0000921531-26-000006 Filed 2026-11-16 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager178,123 SH1,175,612 dollarsHigher by 26,157 Prior quarter: 151,966Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
WOLVERINE ASSET MANAGEMENT LLC Partly reported under another manager174,933 SH1,154,558 dollarsUnchanged Prior quarter: 174,933Open filing 0001279891-26-000016 Filed 2026-11-02 Dispute this row
Empowered Funds, LLC Partly reported under another manager167,905 SH1,108,173 dollarsNot in the prior quarter’s filings read Open filing 0001592828-26-000008 Filed 2026-11-13 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager163,291 SH1,077,720 dollarsHigher by 11,072 Prior quarter: 152,219Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 159,554 SH1,053,056 dollarsLower by 328,730 Prior quarter: 488,284Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
ExodusPoint Capital Management, LP 154,799 SH1,021,673 dollarsHigher by 110,917 Prior quarter: 43,882Open filing 0001736225-26-000013 Filed 2026-11-16 Dispute this row
PRINCIPAL FINANCIAL GROUP INC Partly reported under another manager152,576 SH1,007,002 dollarsNot in the prior quarter’s filings read Open filing 0001126328-26-000225 Filed 2026-11-02 Dispute this row
CREDIT AGRICOLE S A Partly reported under another manager146,300 SH965,580 dollarsUnchanged Prior quarter: 146,300Open filing 0001172661-26-004990 Filed 2026-11-13 Dispute this row
Invesco Ltd. Partly reported under another manager129,348 SH853,697 dollarsLower by 16,717 Prior quarter: 146,065Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. Partly reported under another manager122,700 SH809,820 dollarsUnchanged Prior quarter: 122,700Open filing 0000905148-26-004861 Filed 2026-11-16 Dispute this row
GROUP ONE TRADING LLC Option: Call 119,500 SH788,700 dollarsHigher by 4,500 Prior quarter: 115,000Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row
Nuveen, LLC Partly reported under another manager119,451 SH788,377 dollarsHigher by 5,117 Prior quarter: 114,334Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
Schonfeld Strategic Advisors LLC 119,430 SH788,236 dollarsNot in the prior quarter’s filings read Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row
SummerHaven Investment Management, LLC 113,605 SH749,793 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002336 Filed 2026-10-19 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Sixth Street Partners Management Company, L.P. 1,200,791 SH
  • PALISADE CAPITAL MANAGEMENT, LP 515,059 SH
  • Prosight Management, LP 459,952 SH
  • FRANKLIN RESOURCES INC 166,843 SH
  • Y-Intercept (Hong Kong) Ltd 165,879 SH
  • ARISTEIA CAPITAL, L.L.C. 161,753 SH
  • FULLER THALER ASSET MANAGEMENT, INC. 112,965 SH
  • MACKENZIE FINANCIAL CORP 97,512 SH
  • EVOLVE PRIVATE WEALTH, LLC 70,740 SH
  • Palumbo Wealth Management LLC 58,539 SH
  • HRT FINANCIAL LP 55,443 SH
  • WINTON GROUP Ltd 45,744 SH
  • Integrated Quantitative Investments LLC 38,501 SH
  • LOS ANGELES CAPITAL MANAGEMENT LLC 25,804 SH
  • SG Americas Securities, LLC 23,499 SH
  • Graham Capital Management, L.P. 21,592 SH
  • STIFEL FINANCIAL CORP 20,235 SH
  • Baron Wealth Management LLC 16,239 SH
  • XTX Topco Ltd 14,674 SH
  • ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 14,080 SH
  • BAILARD, INC. 13,600 SH
  • INTECH INVESTMENT MANAGEMENT LLC 13,490 SH
  • RITHOLTZ WEALTH MANAGEMENT 13,197 SH
  • TOCQUEVILLE ASSET MANAGEMENT L.P. 11,095 SH
  • CAPTRUST FINANCIAL ADVISORS 10,137 SH
  • Integrated Wealth Concepts LLC 3,402 SH
  • MEEDER ASSET MANAGEMENT INC 2,057 SH
  • FIDUCIARY FINANCIAL ADVISORS 1,308 SH
  • Pacer Advisors, Inc. 792 SH
  • Truvestments Capital LLC 421 SH
  • KELLEHER FINANCIAL ADVISORS 207 SH
  • BARRETT COMPANY, INC. 175 SH
  • Basecamp Wealth Advisors LLC 151 SH
  • Wealth Enhancement Trust Services, Inc. 145 SH
  • Clearstead Advisors, LLC 127 SH
  • Steward Partners Investment Advisory, LLC 100 SH
  • Rialto Wealth Management, LLC 91 SH
  • Larson Financial Group LLC 91 SH
  • Versant Capital Management, Inc 77 SH
  • SIGNATUREFD, LLC 57 SH
  • WHITTIER TRUST CO OF NEVADA INC 10 SH
  • JPL Wealth Management, LLC 8 SH
  • HUNTINGTON NATIONAL BANK 1 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–13 of 13

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. Steve Cohen (TN09)2024-12-11Sale$1,001 - $15,0002025-01-10
Hon. Josh Gottheimer (NJ05)2021-11-05Sale$1,001 - $15,000JT2021-12-13
Hon. Josh Gottheimer (NJ05)2021-10-18Purchase$1,001 - $15,000JT2021-11-15
Hon. Josh Gottheimer (NJ05)2021-09-15Sale (partial)$1,001 - $15,000JT2021-10-13
Hon. Josh Gottheimer (NJ05)2021-02-23Sale (partial)$1,001 - $15,000JT2021-03-10
Hon. Gilbert Cisneros (CA39)2020-11-24Purchase$1,001 - $15,0002020-12-15
Hon. Gilbert Cisneros (CA39)2020-07-30Purchase$1,001 - $15,0002020-08-19
Hon. Gilbert Cisneros (CA39)2020-06-19Purchase$1,001 - $15,0002020-07-17
Hon. Gilbert Cisneros (CA39)2020-06-30Purchase$1,001 - $15,0002020-07-17
Hon. Josh Gottheimer (NJ05)2020-06-15Purchase$1,001 - $15,000JT2020-07-09
Hon. Josh Gottheimer (NJ05)2020-06-26Purchase$1,001 - $15,000JT2020-07-09
Hon. Steve Cohen (TN09)2020-03-26Sale$1,001 - $15,0002020-04-22
Hon. Steve Cohen (TN09)2019-08-29Sale$15,001 - $50,0002019-09-12

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Oak Hill Advisors LP Common Stock, par value $0.001 per share7.54,014,015.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-008077 Dispute this row
Vanguard Capital Management Common Stock4.922,540,94506/30/2026 Filed 2026-07-31SCHEDULE 13G/AAmendment 1Open filing 0002100119-26-001413 Dispute this row
BlackRock, Inc. Common Stock9.04,651,33906/30/2026 Filed 2026-07-28SCHEDULE 13G/AAmendment 1Open filing 0002012383-26-002482 Dispute this row
Vanguard Capital Management Common Stock5.042,605,09003/31/2026 Filed 2026-04-29SCHEDULE 13GOpen filing 0002100119-26-000472 Dispute this row
Dimensional Fund Advisors LP Common Stock5.32,757,158.0003/31/2026 Filed 2026-04-09SCHEDULE 13GOpen filing 0000354204-26-000520 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 15Open filing 0000102909-26-001106 Dispute this row
STATE STREET CORPORATION COMMON STOCK5.12,696,375.0012/31/2025 Filed 2026-02-09SCHEDULE 13GOpen filing 0000093751-26-000044 Dispute this row
The Vanguard Group Common Stock6.763,553,99912/31/2025 Filed 2026-01-30SCHEDULE 13G/AAmendment 14Open filing 0000102909-26-000130 Dispute this row
BlackRock, Inc. Common Stock7.33,977,53506/30/2025 Filed 2025-07-17SCHEDULE 13GOpen filing 0002052113-25-003027 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,694,798 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015111,180
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to EMERGENT BIOSOLUTIONS INC.